Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease

Neurobiology of Aging

Volumn 33, Issue 8, 2012, Pages 1599-1608

  Ewers, Michael ^a,b   Schmitz, Susanne ^c   Hansson, Oskar ^d   Walsh, Cathal ^c   Fitzpatrick, Annette ^e   Bennett, David ^f   Minthon, Lennart ^d   Trojanowski, John Q ^g   Shaw, Leslie M ^g   Faluyi, Yetunde O ^h   Vellas, Bruno ⁱ   Dubois, Bruno ^j   Blennow, Kaj ^k   Buerger, Katharina ^l   Teipel, Stefan J ^m,n   Weiner, Michael ^a,b   Hampel, Harald ^o  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d LUND UNIVERSITY   (Sweden)

^e UNIVERSITY OF WASHINGTON   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h ADDENBROOKE S HOSPITAL   (United Kingdom)

ⁱ UNIVERSITÉ DE TOULOUSE   (France)

^j INSERM   (France)

^k SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^l LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^m UNIVERSITY OF ROSTOCK   (Germany)

ⁿ GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^o GOETHE UNIVERSITY   (Germany)

more..

Author keywords

A 1 42; Alzheimer's disease; Body mass index; Cerebrospinal fluid; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BODY MASS; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BODY MASS INDEX; BRAIN; COGNITION DISORDERS; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREVALENCE; PROGNOSIS; STATISTICS AS TOPIC; TAU PROTEINS; UNITED STATES;

EID: 84861865381     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.05.005     Document Type: Article

References (53)

1. Barrett-Connor E., Edelstein S., Corey-Bloom J., Wiederholt W. Weight loss precedes dementia in community-dwelling older adults. J. Nutr. Health Aging 1998, 2:113-114.
2. Berlinger W.G., Potter J.F. Low body mass index in demented outpatients. J. Am. Geriatr. Soc 1991, 39:973-978.
3. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
4. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003, 2:605-613.
5. Buchman A.S., Schneider J.A., Leurgans S., Bennett D.A. Physical frailty in older persons is associated with Alzheimer disease pathology. Neurology 2008, 71:499-504.
6. Buchman A.S., Schneider J.A., Wilson R.S., Bienias J.L., Bennett D.A. Body mass index in older persons is associated with Alzheimer disease pathology. Neurology 2006, 67:1949-1954.
7. Buchman A.S., Wilson R.S., Bienias J.L., Shah R.C., Evans D.A., Bennett D.A. Change in body mass index and risk of incident Alzheimer disease. Neurology 2005, 65:892-897.
8. Buerger K., Ewers M., Pirttila T., Zinkowski R., Alafuzoff I., Teipel S.J., DeBernardis J., Kerkman D., McCulloch C., Soininen H., Hampel H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006, 129:3035-3041.
9. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch. Neurol 2009, 66:300-305.
10. Cronin-Stubbs D., Beckett L.A., Scherr P.A., Field T.S., Chown M.J., Pilgrim D.M., Bennett D.A., Evans D.A. Weight loss in people with Alzheimer's disease: a prospective population based analysis. BMJ 1997, 314:178-179.
11. Doty R.L., Reyes P.F., Gregor T. Presence of both odor identification and detection deficits in Alzheimer's disease. Brain Res. Bull 1987, 18:597-600.
12. Dumont C., Voisin T., Nourhashemi F., Andrieu S., Koning M., Vellas B. Predictive factors for rapid loss on the mini-mental state examination in Alzheimer's disease. J. Nutr. Health Aging 2005, 9:163-167.
13. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
14. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol 2006, 59:512-519.
15. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol 2007, 64:343-349.
16. Ferrucci L., Guralnik J.M., Studenski S., Fried L.P., Cutler G.B., Walston J.D. Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report. J. Am. Geriatr. Soc 2004, 52:625-634. Interventions on Frailty Working Group.
17. Fitzpatrick A.L., Kuller L.H., Lopez O.L., Diehr P., O'Meara E.S., Longstreth W.T., Luchsinger J.A. Midlife and late-life obesity and the risk of dementia: Cardiovascular Health Study. Arch. Neurol 2009, 66:336-342.
18. Franklin C.A., Karkeck J. Weight loss and senile dementia in an institutionalized elderly population. J. Am. Diet. Assoc 1989, 89:790-792.
19. Gazdzinski S., Kornak J., Weiner M.W., Meyerhoff D.J. Body mass index and magnetic resonance markers of brain integrity in adults. Ann. Neurol 2008, 63:652-657.
20. Gillette Guyonnet S., Abellan Van Kan G., Alix E., Andrieu S., Belmin J., Berrut G., Bonnefoy M., Brocker P., Constans T., Ferry M., Ghisolfi-Marque A., Girard L., Gonthier R., Guerin O., Hervy M.P., Jouanny P., Laurain M.C., Lechowski L., Nourhashemi F., Raynaud-Simon A., Ritz P., Roche J., Rolland Y., Salva T., Vellas B. IANA (International Academy on Nutrition and Aging) expert group: Weight loss and Alzheimer's disease. J. Nutr. Health Aging 2007, 11:38-48. International Academy on Nutrition and Aging Expert Group.
21. Grundman M., Corey-Bloom J., Jernigan T., Archibald S., Thal L.J. Low body weight in Alzheimer's disease is associated with mesial temporal cortex atrophy. Neurology 1996, 46:1585-1591.
22. Gustafson D., Rothenberg E., Blennow K., Steen B., Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch. Intern. Med 2003, 163:1524-1528.
23. Hampel H., Buerger K., Zinkowski R., Teipel S.J., Goernitz A., Andreasen N., Sjoegren M., DeBernardis J., Kerkman D., Ishiguro K., Ohno H., Vanmechelen E., Vanderstichele H., McCulloch C., Moller H.J., Davies P., Blennow K. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry 2004, 61:95-102.
24. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006, 5:228-234.
25. Herukka S.K., Helisalmi S., Hallikainen M., Tervo S., Soininen H., Pirttilä T. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol. Aging 2007, 28:507-514.
26. Kivipelto M., Ngandu T., Fratiglioni L., Viitanen M., Kåreholt I., Winblad B., Helkala E.L., Tuomilehto J., Soininen H., Nissinen A. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch. Neurol 2005, 62:1556-1560.
27. Knopman D.S., DeKosky S.T., Cummings J.L., Chui H., Corey-Bloom J., Relkin N., Small G.W., Miller B., Stevens J.C. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1143-1153.
28. Knopman D.S., Edland S.D., Cha R.H., Petersen R.C., Rocca W.A. Incident dementia in women is preceded by weight loss by at least a decade. Neurology 2007, 69:739-746.
29. Luchsinger J.A., Patel B., Tang M.X., Schupf N., Mayeux R. Measures of adiposity and dementia risk in elderly persons. Arch. Neurol 2007, 64:392-398.
30. Lunn D.J., Thomas A., Best N., Spiegelhalter D.J. WinBUGS-a Bayesian modelling framwork: concepts, structure, and extensibility Stat. Comput 2000, 10:325-337.
31. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
32. Morgan D., Gordon M.N. Amyloid, hyperactivity, and metabolism: Theoretical comment on Vloeberghs et al. (2008). Behav. Neurosci 2008, 122:730-732.
33. Nourhashémi F., Deschamps V., Larrieu S., Letenneur L., Dartigues J.F., Barberger-Gateau P. Personnes Agées Quid. Body mass index and incidence of dementia: the PAQUID study. Neurology 2003, 60:117-119. PAQUID study.
34. Olsson A., Vanderstichele H., Andreasen N., De Meyer G., Wallin A., Holmberg B., Rosengren L., Vanmechelen E., Blennow K. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem 2005, 51:336-345.
35. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol 1999, 56:303-308.
36. Plassman B.L., Langa K.M., Fisher G.G., Heeringa S.G., Weir D.R., Ofstedal M.B., Burke J.R., Hurd M.D., Potter G.G., Rodgers W.L., Steffens D.C., Willis R.J., Wallace R.B. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007, 29:125-132.
37. Reijn T.S.M., Rikkert M.O., van Geel W.J.A., de Jong D., Verbeek M.M. Diagnostic Accuracy of ELISA and xMAP technology for analysis of amyloid {beta}42 and tau proteins. Clin. Chem 2007, 53:859-865.
38. Rolland Y., Czerwinski S., Abellan Van Kan G., Morley J.E., Cesari M., Onder G., Woo J., Baumgartner R., Pillard F., Boirie Y., Chumlea W.M., Vellas B. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J. Nutr. Health Aging 2008, 12:433-450.
39. Schwartz M.W., Woods S.C., Porte D., Seeley R.J., Baskin D.G. Central nervous system control of food intake. Nature 2000, 404:661-671.
40. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann. Neurol 2009, 65:403-413.
41. Spiegelhalter D.J., Myles J.P., Jones D.R., Abrams K.R. Methods in health service research. An introduction to Bayesian methods in health technology assessment. BMJ 1999, 319:508-512.
42. Stewart R., Masaki K., Xue Q.L., Peila R., Petrovitch H., White L.R., Launer L.J. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch. Neurol 2005, 62:55-60.
43. Strozyk D., Blennow K., White L.R., Launer L.J. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003, 60:652-656.
44. Tapiola T., Overmyer M., Lehtovirta M., Helisalmi S., Ramberg J., Alafuzoff I., Riekkinen P., Soininen H. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport 1997, 8:3961-3963.
45. Vanderstichele H., Van Kerschaver E., Hesse C., Davidsson P., Buyse M.A., Andreasen N., Minthon L., Wallin A., Blennow K., Vanmechelen E. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 2000, 7:245-258.
46. Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van Der Perre B., Sjögren M., Andreasen N., Blennow K. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 2000, 285:49-52.
47. Vemuri P., Wiste H.J., Weigand S.D., Shaw L.M., Trojanowski J.Q., Weiner M.W., Knopman D.S., Petersen R.C., Jack C.R. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009, 73:287-293. Alzheimer's Disease Neuroimaging Initiative.
48. Visser P.J., Verhey F., Knol D.L., Scheltens P., Wahlund L.O., Freund-Levi Y., Tsolaki M., Minthon L., Wallin A.K., Hampel H., Bürger K., Pirttila T., Soininen H., Rikkert M.O., Verbeek M.M., Spiru L., Blennow K. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009, 8:619-627.
49. Vloeberghs E., Van Dam D., Franck F., Serroyen J., Geert M., Staufenbiel M., De Deyn P.P. Altered ingestive behavior, weight changes, and intact olfactory sense in an APP overexpression model. Behav. Neurosci 2008, 122:491-497.
50. Wang L., Larson E.B., Bowen J.D., van Belle G. Performance-based physical function and future dementia in older people. Arch. Intern. Med 2006, 166:1115-1120.
51. Whitmer R.A., Gunderson E.P., Barrett-Connor E., Quesenberry C.P., Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 2005, 330:1360.
52. Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Wahlund L.O., Nordberg A., Bäckman L., Albert M., Almkvist O., Arai H., Basun H., Blennow K., de Leon M., DeCarli C., Erkinjuntti T., Giacobini E., Graff C., Hardy J., Jack C., Jorm A., Ritchie K., van Duijn C., Visser P., Petersen R.C. Mild cognitive impairment--beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J. Intern. Med 2004, 256:240-246.
53. Yaffe K., Kanaya A., Lindquist K., Simonsick E.M., Harris T., Shorr R.I., Tylavsky F.A., Newman A.B. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004, 292:2237-2242.